Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

se of nucleoside analogues alone or in combination with other antiretrovirals. Viread is not approved for the treatment of chronic hepatitis B and the safety and efficacy of Viread have not been established in patients coinfected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Viread. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are co-infected with HIV and HBV and discontinue Viread. If appropriate, initiation of anti-hepatitis B therapy may be warranted.

Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported in association with the use of Viread. It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy with Viread and as clinically appropriate during therapy. Coadministration of Viread and didanosine should be undertaken with caution. Patients should be monitored closely for didanosine-associated adverse events, and didanosine should be discontinued if these occur. Patients on atazanavir and lopinavir/ritonavir plus Viread should be monitored for Viread-associated adverse events, and Viread should be discontinued if these occur. When co-administered with Viread, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg. Atazanavir without ritonavir should not be co-administered with Viread.

Decreases in bone mineral density (BMD) at the lumbar spine and hip have been seen with the use of Viread. The effects of Viread-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown. Changes in body fat have been observed in patients taking anti-HIV medicines. The cause and long-term health effect of these changes are unknown. Immune Reconstitution Syndrome has been reported in patients treated with combination therapy, including Viread.

The most com
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... Berger Health System, recognized as one of the ... to AutoCarousel® HD by Talyst, a leader of pharmacy ... has a built-to-last 10 years guarantee. Berger ... is also implementing AutoPharm®, AutoPack™ and AutoLabel® to help ...
... Lineagen, Inc., an innovative molecular diagnostics company focused on ... nonprofit subsidiary of the National Multiple Sclerosis Society, today ... validation of a blood-based assay for multiple sclerosis (MS). ... test that can aid clinicians in diagnosing MS, distinguishing ...
Cached Medicine Technology:Berger Health System Partners With Pharmacy Automation Leader to Improve Patient Safety 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 3Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 4
(Date:7/12/2014)... (PRWEB) July 12, 2014 Wright & Schulte ... clients in Just For Men Lawsuits (case #59776/2014), announces ... consumers of reports that allege the popular hair dye, Just ... burns to their face, neck and other areas. In addition ... For Men chemical burns , the advertisements being run by ...
(Date:7/12/2014)... July 12, 2014 The largest pure ... is pleased to announce that it will be opening ... new facility will join four Atlanta-based Nova Medical Centers’ ... at 3209 Deans Bridge Road, and will be open ... , “With Nova’s treatment philosophy of rapid return-to-work ...
(Date:7/11/2014)... Va. (PRWEB) July 11, 2014 The ... at America’s 55 poison centers are commending Senator Bill ... Poison Prevention Act of 2014 on July 10, 2014. ... U.S. Consumer Products Safety Commission (CPSC) to enact rules ... to consumers. , Senate co-sponsors of the ...
(Date:7/11/2014)... 2014 Butler Mobility has recently updated the ... Lifts . Previously the two standard colors were beige ... earth tone colors as standard colors at no additional charge! ... home but will enhance the beauty of the stairway. ... color scheme or individual décor. , The new selection of ...
(Date:7/11/2014)... Volunteers from Scientology Churches and ... with drug education lectures, forums and conferences, information stands, ... around the world. , Drug abuse is an international ... Abuse, abuse of alcohol and illicit drugs costs more ... decreased productivity and healthcare. , In the face ...
Breaking Medicine News(10 mins):Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3
... FRANCISCO, March 9 Medivation, Inc. (Nasdaq: ... host a teleconference and webcast with management to discuss fourth ... business update on Monday, March 16, 2009, at 4:30 p.m. ... year ended December 31, 2008 will be released after markets ...
... March 9 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... hearing to appeal to a Listings Qualification Panel ("Panel") ... the Company,s common stock from The Nasdaq Capital Market ... requires the Company to have a minimum of $2,500,000 ...
... In Kentucky, nearly one out of every two ... barely a quarter of the dentists accept the insurance; ... when it comes to seeing a dentist or receiving ... Consumer Healthcare, manufacturer of Aquafresh(R) and Sensodyne(R), has donated ...
... risk by 45%, study finds, , , MONDAY, March 9 (HealthDay News) ... of gout, according to researchers who studied almost 47,000 men over ... the men developed gout. Compared with those whose vitamin C intake ... the risk for gout was 17 percent lower among men with ...
... care, closure important for dying, families and docs, study finds, ... more that can be done for terminally ill patients, and ... death, many feel as if their doctors have abandoned them, ... their families, continuing care is helpful for all concerned, and ...
... forensics cameras will survive., , , ... , , , ... , , , ... , , , Lights, Camera, Ka-Boom! , Cheap, ...
Cached Medicine News:Health News:Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009 2Health News:Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq 2Health News:Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq 3Health News:GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia 2Health News:More Vitamin C May Mean Less Chance of Gout 2Health News:Dying Feel Abandoned by Docs in the End 2Health News:Dying Feel Abandoned by Docs in the End 3Health News:Ka-Boom!!! 2Health News:Ka-Boom!!! 3Health News:Ka-Boom!!! 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: